Navigation Links
The Quantum Group, Inc. Announces Separation of Units

WELLINGTON, Fla., Jan. 10 /PRNewswire-FirstCall/ -- The Quantum Group, Inc. (Amex: QGP, QGP.U) ( today announced that it has been notified by Paulson Investment Company, a wholly owned subsidiary of Paulson Capital Corp. (Nasdaq: PLCC) and the lead underwriter for the December 2007 public offering, that beginning Monday, January 14, 2008, the Company units will separate into its individual component parts; three shares of common stock, two Class A warrants and two Class B warrants. The units, trading under the symbol QGP.U, will cease to trade as of the close of business on Friday, January 11, 2008. The separation of the units will be voluntary from Monday, January 14, 2008 to Wednesday, January 16, 2008.

At the open of the market on Monday, January 14, 2008, unit holders may separately trade the common stock, Class A warrants and Class B warrants included in such units. The symbols for the common stock, Class A warrants and Class B warrants are QGP, QGP.WS.A and QGP.WS.B, respectively.

About the Company

The Quantum Group, Inc. is a Florida-based organization. The Company builds and manages healthcare systems and offers consulting and outsourcing services that will be leveraged by leading-edge technology to the nation's largest and fastest growing industry- healthcare.

The Company is engaged in the development and execution of a series of innovative technology initiatives designed to make Quantum one of the state's leading providers of business solutions for the healthcare industry. Through its growing number of nearly 1,600 contracted physicians and managed care relationships in the state of Florida, the Company believes it is positioned to bring increased efficiencies to the Florida healthcare industry.

Certain statements contained in this news release, which are not based on historical facts, are forward-looking statements as the term is defined in the Private Securities Litigation Reform Act of 1995, and are subject to substantial uncertainties and risks in part detailed in the respective company's Securities and Exchange Commission 10-KSB, 10-QSB, S-8 and 8-K filings (and amendments thereto) that may cause actual results to materially differ from projections. Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "may," "anticipates," "believes," "should," "intends," "estimates" and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by these forward-looking statements. Such risk factors include, without limitation, the ability of the Company to properly execute its business model, to raise substantial and immediate additional capital to implement its business model, to attract and retain executive, management and operational personnel, to negotiate favorable current debt and future capital raises, to negotiate favorable agreements with a diversified provider base and to continue to supply the services needed by its HMO clients as well physician clients. The Company does not undertake any obligation to publicly update any forward-looking statements. As a result, investors should not place undue reliance on these forward-looking statements.


Elite Financial Communications Group, LLC

Daniel Conway, Chief Strategist

407.585.1080 or via email at


Danielle Amodio

Vice President, Corporate Communications

The Quantum Group, Inc.


SOURCE The Quantum Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Quantum light beams good for fast technology
2. Quantum Foundation Makes a Half Million Dollars Available to Federally Qualified Health Centers
3. American Stock Exchange Lists the Common Stock and Units of The Quantum Group, Inc.
4. The Quantum Group, Inc. Completes $13.2 Million Public Offering and Initiates Trading on the American Stock Exchange Under Symbol QGP
5. Results promising for computational quantum chemical methods for drug development
6. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
7. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
8. Air Methods Completes Acquisition of FSS Airholdings, Inc., Parent Company of CJ Systems Aviation Group, Inc.
9. Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007
10. The Mattson Jack Group, Inc. Announces the Release of the New Comorbidity Database(TM)
11. Congress Declares Long Term Care Awareness Week - Long Term Care Group, Inc. Continues Related Work
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology: